Leerink Partnrs Has Strong Forecast for Cencora Q1 Earnings

Cencora, Inc. (NYSE:COR) – Equities research analysts at Leerink Partnrs boosted their Q1 2025 earnings per share (EPS) estimates for Cencora in a report released on Wednesday, November 6th. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings per share of $3.45 for the quarter, up from their previous forecast of $3.43. The consensus estimate for Cencora’s current full-year earnings is $13.64 per share. Leerink Partnrs also issued estimates for Cencora’s Q2 2025 earnings at $4.12 EPS, Q3 2025 earnings at $3.73 EPS, Q4 2025 earnings at $3.70 EPS, FY2025 earnings at $14.99 EPS, FY2027 earnings at $18.91 EPS and FY2028 earnings at $20.72 EPS.

Other research analysts have also issued research reports about the stock. Leerink Partners reduced their price objective on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. Evercore ISI lifted their target price on Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a report on Thursday. Robert W. Baird raised their price target on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research report on Thursday. Bank of America reissued a “neutral” rating and set a $245.00 target price (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Finally, UBS Group lifted their price target on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research note on Thursday. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $271.20.

Cencora Stock Up 1.0 %

NYSE:COR opened at $247.76 on Friday. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. Cencora has a 12-month low of $191.11 and a 12-month high of $250.80. The firm has a market capitalization of $48.82 billion, a P/E ratio of 32.99, a P/E/G ratio of 1.49 and a beta of 0.44. The stock’s fifty day simple moving average is $231.77 and its 200-day simple moving average is $230.76.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, November 6th. The company reported $3.34 EPS for the quarter, topping the consensus estimate of $3.21 by $0.13. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The company had revenue of $79.05 billion during the quarter, compared to analysts’ expectations of $77.68 billion.

Hedge Funds Weigh In On Cencora

Several institutional investors and hedge funds have recently modified their holdings of the stock. Lake Street Advisors Group LLC lifted its position in Cencora by 1.3% during the third quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company’s stock worth $769,000 after acquiring an additional 43 shares during the last quarter. Financial Advocates Investment Management grew its stake in shares of Cencora by 4.7% in the second quarter. Financial Advocates Investment Management now owns 978 shares of the company’s stock valued at $220,000 after acquiring an additional 44 shares in the last quarter. Venturi Wealth Management LLC increased its position in Cencora by 1.0% during the third quarter. Venturi Wealth Management LLC now owns 4,447 shares of the company’s stock worth $1,001,000 after acquiring an additional 46 shares during the period. Prime Capital Investment Advisors LLC raised its stake in Cencora by 1.2% in the 3rd quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company’s stock worth $848,000 after purchasing an additional 46 shares in the last quarter. Finally, Checchi Capital Advisers LLC boosted its holdings in Cencora by 2.2% in the 2nd quarter. Checchi Capital Advisers LLC now owns 2,217 shares of the company’s stock valued at $499,000 after purchasing an additional 48 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares of the company’s stock, valued at $67,223,750.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 15.80% of the stock is owned by insiders.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be paid a dividend of $0.55 per share. The ex-dividend date is Friday, November 15th. This is a positive change from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a dividend yield of 0.89%. Cencora’s payout ratio is currently 29.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.